Overcoming Key Hurdles in Decentralized Trials with Better Education

Overcoming Key Hurdles in Decentralized Trials with Better Education

Posted Nov 17, 2021 from

Decentralized clinical trials, and their near cousins that apply a hybrid approach of in-person and remote visits, are increasingly seen as a viable solution for biopharma companies and CROs alike. Recent statements by the FDA and EMA support this emphasis, calling out the need for education and training of all constituents in a clinical trial to reduce unwanted protocol deviations and improve overall quality in clinical trial operations.
 


See Topics

See Also

Next Article